贝达喹啉、德拉马尼和普托马尼治疗耐多药结核病对肝功能影响的研究进展  

Research progress on the effects of bedaquiline,delamanid and pretomanid on liver function in the treatment of multidrug-resistant tuberculosis

作　　者：施春晶 刘幸 李龙芬 李文明 张华杰 王戈 曾海燕 刘立 沈凌筠 Shi Chunjing;Liu Xing;Li Longfen;Li Wenming;Zhang Huajie;Wang Ge;Zeng Haiyan;Liu Li;Shen Lingjun(Department of Tuberculosis,Kunming Third People’s Hospital/Yunnan Infectious Disease Clinical Medical Center/The Sixth Affiliated Hospital of Dali University,Kunming 650041,China)

机构地区：[1]昆明市第三人民医院结核科/云南省传染性疾病临床医学中心/大理大学第六附属医院,昆明650041

出　　处：《中国防痨杂志》2024年第12期1560-1565,共6页Chinese Journal of Antituberculosis

基　　金：云南省科技厅科技计划项目(202303AC100026);昆明市卫生健康委员会卫生科研课题项目(2023-03-02-019,2023-03-08-012)。

摘　　要：耐多药结核病的治疗面临诸多挑战,抗结核药贝达喹啉、德拉马尼和普托马尼作为近50年出现的具有新作用靶点的药物,对耐多药结核病表现出良好的治疗潜力,但相关研究表明,它们可影响肝功能导致抗结核药物性肝损伤。作者旨在通过对贝达喹啉、德拉马尼和普托马尼三种抗结核新药单药应用或多药联用下导致的肝功能损伤及相关发生机制及注意事项进行综述,以期为临床使用它们治疗耐多药结核病提供依据和参考。The treatment of multidrug-resistant tuberculosis(MDR-TB)faces many challenges.The anti-TB drugs bedaquiline,delamanid and pretomanid,which are drugs having new therapeutic targets in recent 50 years,show good therapeutic potential for MDR-TB.However,relevant studies have shown that they can affect liver function and cause drug-induced liver injury.The authors reviewed liver function injury caused by single drug or multidrug combination of bedaquiline,delamanid and pretomanid,and its related mechanisms and precautions,in order to provide evidence and reference for the clinical use of them in the treatment of MDR-TB.

关 键 词：贝达喹啉 德拉马尼 普托马尼 结核 抗多种药物性 抗结核药 肝功能不全 

分 类 号：R521[医药卫生—内科学] R575[医药卫生—临床医学]